Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in the Phase 3 BOSTON study, once weekly selinexor, once weekly...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Hematol Oncol
Main Authors: Mateos, Maria V., Gavriatopoulou, Maria, Facon, Thierry, Auner, Holger W., Leleu, Xavier, Hájek, Roman, Dimopoulos, Meletios A., Delimpasi, Sosana, Simonova, Maryana, Špička, Ivan, Pour, Ludĕk, Kriachok, Iryna, Pylypenko, Halyna, Doronin, Vadim, Usenko, Ganna, Benjamin, Reuben, Dolai, Tuphan K., Sinha, Dinesh K., Venner, Christopher P., Garg, Mamta, Stevens, Don A., Quach, Hang, Jagannath, Sundar, Moreau, Philippe, Levy, Moshe, Badros, Ashraf Z., Anderson, Larry D., Bahlis, Nizar J., Cavo, Michele, Chai, Yi, Jeha, Jacqueline, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Richardson, Paul G., Grosicki, Sebastian
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2021
Assuntos:
Letter to the Editor
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8045319/
https://ncbi.nlm.nih.gov/pubmed/33849608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01071-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares